asthma. It increased FEV 1 within one hour of dosing, improved patient summary Background -Leukotriene receptor antsymptom and night-time asthma scores, agonists have been shown to protect and reduced the use of rescue bronchoagainst bronchoconstriction induced by dilators, thus providing further evidence antigens, exercise, and cold air. There are of a role for leukotrienes in the pathorelatively few clinical studies reported in genesis of asthma. patients with asthma. The present study (Thorax 1997;52:523-527) is the first clinical evaluation of pranlukast (SB 205312, ONO-1078) outside Japan in Keywords: leukotriene receptor antagonist, asthma, patients with asthma.
twice daily compared with placebo, in patients hour after the first dose of pranlukast com-UK with asthma. The doses were chosen to assess pared with baseline and this increase was lukast was well tolerated, and no drug established diagnosis of asthma, a forced exrelated changes in haematological and bio-Patients abstained from salbutamol for eight hours. At subsequent visits to the clinic patients were asked not to take their morning drug dose hours prior to this acute bronchodilator test.
Patients were permitted to take inhaled ster-until after the spirometry and PEFR had been measured. They only had measurements made oids (up to 1000 g/day beclomethasone dipropionate or its equivalent) and on-demand for eight hours on the first day of drug dosing.
The primary efficacy variables were the salbutamol during the study. However, they could not take disodium cromoglycate or nedo-trough FEV 1 measured in the morning in the clinic, and morning domiciliary PEFR. Pul-cromil sodium for six weeks or oral steroids for eight weeks before entry to the study. Oral monary function was assessed in the clinic by measuring FEV 1 , forced vital capacity, and methylxanthines, oral and inhaled long acting 2 agonists, inhaled anticholinergics, and oral PEFR three times before the administration of study medication (the highest reading of each antihistamines had to be withdrawn at least five half lives before the start of the study to was used for statistical analysis). Patients also measured their PEFR at home twice a day with ensure no residual effects.
Patients who had poorly controlled asthma, the peak flow meter, before the morning dose and after the evening dose of study medication; an active smoking history (within six months of entry to the study), recent upper or lower each time three values were recorded and the highest value was used on the diary card. Each respiratory infections, or other clinically significant or potentially confounding diseases inhalation of salbutamol and inhaled corticosteroids was also recorded on the diary card, were excluded.
All patients provided written informed con-as well as daytime and night-time asthma symptom severity which was rated on a five point sent before participating in the study, and the protocol was approved by the ethics committee scale: 0=none (no symptoms), 1=mild, 2= moderate, 3=severe, and 4=very severe symp-at each research centre.
toms. The daytime and night-time asthma symptom scores were combined into an overall summary symptom score.
 
The study was of a randomised, double blind, Safety was assessed at each visit based on the incidence of adverse experiences, vital signs, placebo controlled, multicentre, parallel group design with a two week single blind placebo laboratory evaluations, ECG tracings, and physical and respiratory examinations. Patients run-in phase, followed by a four week double blind treatment phase, and a 1-2 week run-who withdrew from the study because of adverse experiences were followed to determine out phase. During the treatment phase patients were randomised to one of three treatment the final outcome of these events. groups: pranlukast 225 mg (n=46), 337.5 mg (n=45), or matching placebo (n=44) twice daily. Both doses of pranlukast and placebo   All analyses of efficacy were performed using were administered as identical capsules.
Patients who successfully completed all data from all patients who received at least one dose of randomised treatment. Analysis of screening assessments (routine history and examination, haematology, biochemistry, urin-variance (ANOVA) was used to assess differences between treatment groups for normally alysis, and 12 lead ECG) and satisfied study inclusion and exclusion criteria were given distributed, continuous variables. Within treatment comparisons were made using paired t placebo capsules on a single blind basis. They were instructed to take capsules with water 30 tests. Because the primary objective of the study was to assess the safety and tolerability of pran-minutes before breakfast (08.00 hours) and in the evening (20.00 hours) after a meal. In lukast, no formal sample size calculations were performed. The goal was to have at least 120 addition, patients were given peak flow meters (mini-Wright, Airmed, Harlow, Essex, UK) patients enrolled to yield at least 90 evaluable patients (30 in each treatment group). For and were instructed in their use. Diary cards were used to record symptom severity and efficacy analyses, statistical tests were performed at a significance level of 5% ( =0.05, use of all medications, including on-demand salbutamol (100 g/actuation). Patients were two tailed test).
The primary between treatment comparisons scheduled to visit the clinic at the same time of day 14 days after screening, at the end were the analyses of trough FEV 1 (the clinic measurement before daily dosage) and morning of one, two, and four weeks of double blind treatment, and 1-2 weeks after treatment was home PEFR measurements. ANOVA was used to analyse the change from trough baseline stopped.
Following the placebo run-in phase, patients values of FEV 1 at each time point following the first dose and the change from baseline who had complied with the treatment regimen and who had completed their diary cards were (highest value at week 0) for trough values on a visit-wise and end point -that is, the last randomised to receive double blind treatment. They attended the clinic in the morning, having available post-baseline measurement -basis.
Paired t tests were used to compare the morning refrained from taking inhaled steroids and salbutamol for eight hours. Baseline FEV 1 and and evening home PEFR measurements with the respective run-in values for each inter-visit peak expiratory flow rate (PEFR) were measured and patients received the first dose of study period, and ANOVA was used for comparisons between treatment groups. Patients who took medication. FEV 1 and PEFR were measured again 30, 60, 90, and 120 minutes after the inhaled salbutamol during the eight hours preceding the visits at weeks 1, 2, and 4 were medication and then hourly for a further six on January 18, 2020 by guest. Protected by copyright. http://thorax.bmj.com/ Thorax: first published as 10.1136/thx.52.6.523 on 1 June 1997. Downloaded from Adverse experiences were tabulated using the of adverse experiences, one patient was withdrawn for a protocol violation, and one was lost to follow up. Forty two patients in the group treated with pranlukast 225 mg twice daily completed the study, as did 42 in the group receiving pranlukast 337.5 mg twice daily and 43 in the placebo group. Of the six patients who discontinued because of adverse experiences, two in the pranlukast 225 mg group, one in the pranlukast 337.5 mg group, and one in the placebo group withdrew because of an exacerbation of asthma, one in pranlukast 337.5 mg group withdrew because of an injury, and one in the pranlukast 337.5 mg group withdrew because of diarrhoea.
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Week period the mean increase in morning home PEFR was statistically significant at all time points for the group treated with pranlukast 337.5 mg and at weeks 1 and 2 for the group given 225 mg pranlukast compared with placebo ( fig 1) . No difference was noted between the pranlukast 225 mg and 337.5 mg treatment groups. The difference in evening home PEFR was not significant.
  
The improvement in trough FEV 1 at week 4 was statistically significant for patients taking pranlukast in a twice daily dose of 225 mg tween the groups were seen at other times. Clinic morning PEFR measurements were significantly improved in both pranlukast treatment groups compared with baseline values, excluded from the analyses of pulmonary function test results for the violating visit(s) only.
although no significant differences were observed between the active treatment groups and Daytime and night-time asthma symptom scores were totalled each day to produce a those receiving placebo.
FEV 1 significantly increased within one hour summary symptom score, and an average of these values was determined for each inter-visit after the first dose of pranlukast, 225 or 337.5 mg, compared with baseline and this period. Paired t tests were used to compare summary symptom scores with scores obtained increase was maintained for eight hours. FEV 1 was also increased in patients treated with during the placebo run-in phase for each intervisit period, and ANOVA was used for between placebo, but this increase was not significant at five, seven, and eight hours (fig 3) . No treatment group comparisons. The use of salbutamol was analysed in a similar manner. differences were found between the groups.
on January 18, 2020 by guest. Protected by copyright. http://thorax.bmj.com/ Thorax: first published as 10.1136/thx.52.6.523 on 1 June 1997. Downloaded from point (p=0.042; 95% CI −0.93 to −0.02), and for night-time asthma scores at weeks 1, 2, and 4 (p<0.05; 95% CI −0.58 to −0.01) and at end point (p=0.016; 95% CI −0.6 to −0.06) (table 2) . No significant changes in daytime symptom scores or use of 2 agonists were seen.

Pranlukast was well tolerated during the four weeks of double blind treatment with study medication. There were no clinically significant differences between the pranlukast and placebo groups in the number of patients reporting specific adverse experiences. The most com- the study medication, and no clinically significant changes attributed to pranlukast were treatment of asthma, and the drug is presently on the market in Japan. Short term clinical studies have shown that pranlukast is well tol- 
